Study, country | Form of economic analysis | Treatment | Comparator | Patient population | Model horizon |
---|---|---|---|---|---|
Taylor et al., 2014 [33] UK | Cost-effectiveness | Ranibizumab | Observation | Patients with ME secondary to CRVO | Lifetime |
Eriksson et al., 2014 [29] Sweden | Cost-effectiveness | Aflibercept | Ranibizumab | Patients with ME secondary to CRVO; average starting age 64Â years | 15Â years |
Duff et al., 2012 [31] USA | Cost-utility | 1) Ranibizumab | 1) Dexamethasone intravitreal implant | Patients with ME secondary to CRVO | 2Â years |
2) Dexamethasone intravitreal implant | 2) Steroids | ||||
Haig et al., 2012 [32] Canada | Cost-utility | Ranibizumab | Observation | Patients (66–68 years) with ME secondary to CRVO | Lifetime |
Vincente et al., 2013 [30] Canada | Cost-effectiveness | Dexamethasone intravitreal implant | Observation | Patients with ME and vision loss secondary to CRVO | Lifetime |
Hayward et al., 2011 [34] UK | Cost-utility | Dexamethasone intravitreal implant | Observation | Patients with ME secondary to CRVO from GENEVA 008 and 009 clinical trial studies | Lifetime |
Kowalski et al., 2011 [35] USA | Cost-utility | Dexamethasone intravitreal implant | Observation | Individual patient-level data were pooled from phase 3 studies of patients with ME following CRVO; mean age 65Â years and study-eye visual acuity of 20/80 | Lifetime |